CompletedNot Applicable

Non-invasive Monitoring: Impact on Patient Management and Outcomes

United States54 participantsStarted 2024-01-19

Plain-language summary

Enhancing patient monitoring in SNFs and ALFs is crucial due to challenges in recognizing deteriorating health. Gaps in vital sign checks lead to missed indicators and adverse outcomes. Turtle Shell Technologies' Dozee Pro NX offers continuous non-invasive monitoring, alerting healthcare providers of vital sign changes. This clinical study aims to evaluate Dozee Pro Nx's impact on patient outcomes, practitioner efficiency, and healthcare costs in SNFs and ALFs, addressing gaps in care delivery.

Who can participate

Age range18 Months – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older. * Weight between 40kg-120kgs Exclusion Criteria: * Terminal illness with a life expectancy of less than 1 month. * Have any condition that could interfere with the subject's ability to lie flat or stable on the bed * Needs the use of equipment whose operation can interfere with Investigation System operations * Patients planned to be transferred from the facility within 72 hours * Prisoners * Pregnant

What they're measuring

Number of Care Escalation and/or Transfers (Subgroup- ER visits, Surgical Interventions & Hospitalizations, ICU Admissions),

Timeframe: 3 months

Trial details

NCT IDNCT06270953

SponsorTurtle Shell Technologies Pvt. Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-04-30

View on ClinicalTrials.gov More No Specific Medical Conditions or Disease States trials